Biologics Market Report 2026

Biologics Market Overview

• Biologics market size has reached to $495.56 billion in 2025 • Expected to grow to $827.24 billion in 2030 at a compound annual growth rate (CAGR) of 11.2% • Growth Driver: Personalized Medicine Fueling Growth In The Biologics Market • Market Trend: Advancing Efficiency Through Next-Generation Biomanufacturing • North America was the largest region in 2025 and Middle East is the fastest growing region.

The key promising market opportunities in the biologics market include: • Parenteral (Segmentation By Route Of Administration) → Expected gain of $201010.36 Million • Prescription-Based Drugs (Segmentation By Mode Of Purchase) → Expected gain of $172346.96 Million • Branded Drugs (Segmentation By Drug Classification) → Expected gain of $145994.09 Million

What Is Covered Under Biologics Market?

Biologics are medications made from organic materials that can be used to treat a wide range of illnesses, and they are frequently used to treat immune-related illnesses. The interesting aspect is that biologics are separated from various natural sources, whether they be carbohydrates, proteins, nucleic acids, or a complex mixture of these materials. The main types of biologics are monoclonal antibodies (MAbs), therapeutic proteins, and vaccines. Monoclonal antibodies, or mAbs, are created in a laboratory to combat a specific infection. The various routes of administration include oral, parenteral, and others that are distributed by hospital pharmacies, retail pharmacies or drug stores, and others.

What Is The Biologics Market Growth Forecast?

The biologics market size is expected to see rapid growth in the next few years. It will grow to $827.24 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to development of novel monoclonal antibodies, expansion of mRNA and viral vector vaccines, increasing adoption of personalized biologic therapies, growing government support and funding for biologics, integration of digital health and patient monitoring platforms. Major trends in the forecast period include rising adoption of monoclonal antibodies and therapeutic proteins, growth in vaccine development including mrna and viral vector vaccines, expansion of prescription-based biologics and hospital pharmacy distribution, increasing focus on personalized medicine and targeted biologic therapies, integration of biologics with advanced healthcare solutions and patient monitoring.

What Is The Driver Of The Biologics Market?

The increasing demand for personalized medicine is driving significant growth in the global biologics market. Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare and medical treatment to the individual characteristics of each patient. Personalized medicine offers the ability to customize biological treatments to a patient's specific genetic and clinical profile transforming the healthcare landscape. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the biologics industry going forward.

How Will The Drivers Impact Growth In The Global Biologics Market?

• Rising Prevalence of Chronic Diseases (Medium) – The rising prevalence of chronic diseases will become a key driver of growth in the biologics market by 2030. As biologics, valued for their high specificity and ability to interact with complex biological systems, are increasingly favoured over traditional small-molecule drugs for treating these conditions. With an aging global population and a surge in lifestyle-related health problems, both healthcare providers and pharmaceutical companies are prioritizing the development of innovative biologic therapies to meet growing medical needs. This escalating disease burden is spurring increased investment in biologics research, clinical trials, and manufacturing capabilities, thereby fueling the expansion of the biologics market. As a result, the rising prevalence of chronic diseases is anticipated to contributing to a 1.5% annual growth in the market. • Increasing R&D Investments by Pharma Companies (Low) – The increasing research and development investments by pharma companies will emerge as a major factor driving the expansion of the biologics market by 2030. As these companies intensify their focus on developing innovative biologics for treating complex and chronic conditions, they are allocating significant resources toward advanced technologies that improve R&D efficiency and accuracy. These investments are enabling progress in areas such as large-scale genomic research, cell line engineering, and precision medicine all critical to biologics discovery and production. Greater funding is also accelerating the adoption of high-throughput screening, state-of-the-art lab infrastructure, and integrated development processes, thereby speeding up biologics innovation. Consequently, the increasing research and development investments by pharma company’s capabilities is projected to contributing to a 0.9% annual growth in the market. • Rise in Aging Population (Low) – The rise in aging population processes will serve as a key growth catalyst for the biologics market by 2030, As the global elderly population rises, so does the demand for advanced therapies that can manage complex health issues with improved efficacy and reduced side effects. This demographic trend is pushing pharmaceutical companies to fast-track the development of biologics, with a focus on therapies designed to meet the specific needs of aging individuals. Therefore, this rise in aging population operations is projected to supporting to a 0.5% annual growth in the market. • Rapid Adoption of Monoclonal Antibodies (Low) – The rapid adoption of monoclonal antibodies will become a significant driver contributing to the growth of the biologics market by 2030. As for their high specificity, strong efficacy, and broad applicability in treating conditions such as cancer, autoimmune diseases, and infectious illnesses, monoclonal antibodies are becoming a central focus for pharmaceutical companies. Their rising demand is further bolstered by public funding initiatives aimed at advancing precision medicine and life sciences innovation, accelerating the development of these targeted therapies. Additionally, national programs supporting advanced therapeutics, along with streamlined regulatory pathways, are enabling faster approval and market entry. This proactive approach to maintenance supports operational efficiency and cost savings across production environments. Consequently, the rapid adoption of monoclonal antibodies is projected to contributing to a 0.3% annual growth in the market.

How Will The Restraints Impact Growth In The Global Biologics Market?

• Cold Chain and Storage Challenges (Medium) – Cold Chain and Storage Challenges will restrict the growth of the Biologics market during the forecast period. Biologics require strict temperature-controlled storage and transportation throughout the supply chain, from manufacturing to patient administration. Maintaining the cold chain across distribution networks presents significant logistical challenges and costs. Any temperature deviation can compromise product efficacy and safety, leading to costly product losses and waste. These cold chain requirements limit market reach, particularly in regions with inadequate infrastructure. • Risk of Cross-Contamination (Low) – Risk of Cross-Contamination will restrict the growth of the Biologics market during the forecast period. Biologics manufacturing is susceptible to cross-contamination, requiring stringent aseptic processing and separation between different product lines. The complexity of manufacturing processes increases the risk of product recalls, regulatory issues, and production interruptions. These contamination concerns add to manufacturing costs and can limit production capacity, affecting market growth. • Impact of Trade War and Tariffs (Low) – Impact of Trade War and Tariffs will restrict the growth of the Biologics market during the forecast period. Biologics manufacturing relies on global supply chains for raw materials, cell lines, and production equipment. Trade tariffs and restrictions can disrupt these supply chains and increase costs. Trade barriers may also affect the international distribution and availability of biologic medicines, limiting patient access and market growth.

Key Players In The Global Biologics Market

Major companies operating in the biologics market are Merck & Co. Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Apotex, Gilead Sciences

Global Biologics Market Trends and Insights

Major companies operating in the biologics market are focusing on developing innovative products such as biosimilars to provide cost-effective alternatives to original biologic therapies. Biosimilars are biologic products highly similar to an already approved reference biologic, with no significant differences in safety, efficacy, or quality, helping reduce treatment costs and increase patient access to advanced therapies. For instance, in July 2025, Biocon Biologics, a subsidiary of Biocon Limited, an India-based biopharmaceutical company, launched Nepexto, a biosimilar to Enbrel (etanercept), in Australia. Nepexto is a fusion-protein biologic designed to inhibit tumor necrosis factor-alpha (TNF-α), a key inflammatory mediator in autoimmune conditions. It is composed of recombinant DNA-derived protein that mimics the binding activity of the original etanercept molecule, delivering comparable efficacy and safety while making treatment more accessible. Its unique features include high biosimilarity backed by robust clinical data, regulatory approvals, and an established supply chain via its local partner Generic Health making it a strong option for long-term management of diseases such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

What Are Latest Mergers And Acquisitions In The Biologics Market?

In October 2025, Terumo Corporation, a Japan-based healthcare technology company, acquired the drug-product plant and quality-control laboratory operations of WuXi Biologics in Leverkusen, Germany for an undisclosed amount. With this acquisition, Terumo Corporation aims to expand its contract-development and manufacturing organization (CDMO) footprint in Europe, enhance its integrated services for injectable therapeutics, and improve global responsiveness for biopharmaceutical clients. WuXi Biologics GmbH is a Germany-based life-sciences company that specializes in providing biopharmaceutical contract development and manufacturing services for biologics and advanced therapies.

What Defines the Biologics Market?

The biologics market consists of sales of tumor necrosis factor inhibitors, Interleukin inhibitors, B-cells inhibitors, and T-cells inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biologics Market Report 2026?

The biologics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biologics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.